

March 10, 2025

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Sub: Intimation related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with Orchid Pharma Limited ("Company" / "Amalgamated Company") and their respective shareholders and creditors ("the Scheme") under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Dear Sir/Madam,

This is in furtherance to our earlier intimation dated September 27, 2024, wherein we have informed that the Company has e-filed a Joint Company Application on September 26, 2024 with the Hon'ble National Company Tribunal, Chennai Bench ("Hon'ble NCLT"), along with the Amalgamating Company in relation to the Scheme.

In this regard, we would like to inform you that the Hon'ble NCLT have heard the matter under consideration, in the hearing held on March 05, 2025 and have reserved its order for formal pronouncement in due course. Further, the interim order has been uploaded on the website of Hon'ble NCLT today, i.e., March 10, 2025, communicating the reservation of order.

Once the NCLT order is formally pronounced, we will intimate the same to the stock exchange(s).

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No. F10698